Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cel-Sci Corporation Common Stock
(NY:
CVM
)
1.580
-0.040 (-2.48%)
Streaming Delayed Price
Updated: 9:56 AM EDT, Sep 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cel-Sci Corporation Common Stock
< Previous
1
2
3
4
5
Next >
CEL-SCI Reports Fiscal Third Quarter 2026 Results
August 17, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
August 04, 2026
From
CEL-SCI Corporation
Via
Business Wire
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
July 30, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
July 13, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
June 24, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of Offering
June 16, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
June 16, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Announces Pricing of Offering
June 14, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
June 12, 2026
From
CEL-SCI Corporation
Via
Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes $7.2 Million Public Offering
May 19, 2026
Via
Investor Brand Network
CEL-SCI Reports Fiscal Second Quarter 2026 Results
May 18, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of Public Offering
May 13, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Announces Pricing of Public Offering
May 11, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
May 11, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal First Quarter 2026 Results
February 18, 2026
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2025 Results
December 29, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $10 Million Public Offering
August 29, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $10 Million Public Offering
August 27, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering
August 27, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
August 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
August 13, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
July 14, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
July 11, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
July 11, 2025
From
CEL-SCI Corporation
Via
Business Wire
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
June 18, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of Public Offering
May 23, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of Public Offering
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Proposed Public Offering
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 21, 2025
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Combination of Common Stock
May 19, 2025
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
